Efficacy of UDCA with Atorvastatin, and Ezetimibe on Gallstone Disease

Comparison of the Efficacy of UDCA with Atorvastatin, and Ezetimibe in the Treatment of Gallstone Disease :A Randomized, Double-Blind, Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260313068983N1

Enrollment

Registered

2026-05-05

Start date

2026-04-20

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calculus of gallbladder without cholecystitis. Calculus of gallbladder without cholecystitis

Interventions

Intervention 1: Control group: Treatment with 600 mg UDCA daily + placebo. Intervention 2: Intervention group: Treatment with 600 mg UDCA daily and 20 mg Atorvastatin daily. Intervention 3: Interventi

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18 to 60 years Gallstone in sonography Informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Prior diagnosis of dyslipidemia, thyroid disorders, coagulation disorders Smocking, alcohol consumption, drug abuse Tacking medications that influence lipid metabolism

Design outcomes

Primary

Measure	Time frame
Number of gallstones. Timepoint: At the beginning, after six months. Method of measurement: Ultrasonography.;The total size of gallstones. Timepoint: At the beginning, after six months. Method of measurement: Ultrasonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaleh Azadbakht

Khoram-Abad University of Medical Sciences

amiralihatami@sums.ac.ir+98 66 3340 9949

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026